原发性纵隔B细胞淋巴瘤治疗的研究进展

doi:10.3760/cma.j.issn.1673-422X.2019.08.013

国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (8): 505-508.doi: 10.3760/cma.j.issn.1673-422X.2019.08.013

原发性纵隔B细胞淋巴瘤治疗的研究进展

相明月¹ 王丽丽² 韩大力¹

¹山东省肿瘤防治研究院（山东省肿瘤医院）放疗科，山东第一医科大学（山东省医学科学院），济南 250117；²山东省肿瘤防治研究院（山东省肿瘤医院）骨与软组织肿瘤外科，山东第一医科大学（山东省医学科学院），济南 250117

收稿日期:2019-03-20 修回日期:2019-06-23 出版日期:2019-08-08 发布日期:2019-10-31
通讯作者: 韩大力 E-mail:dalihan_sdch@163.com
作者简介:相明月和王丽丽对本文有同等贡献

Progress of treatment for primary mediastinal B-cell lymphoma

Xiang Mingyue¹, Wang Lili², Han Dali¹

¹Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy Medical Sciences, Jinan 250117, China; ²Surgery of Bone and Soft Tissue Tumors, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy Medical Sciences, Jinan 250117, China

Received:2019-03-20 Revised:2019-06-23 Online:2019-08-08 Published:2019-10-31
Contact: Han Dali E-mail:dalihan_sdch@163.com
About author:Xiang Mingyue and Wang Lili are contributed equally to this article

摘要/Abstract

摘要： 原发性纵隔B细胞淋巴瘤（PMBCL）是一种具有独特临床病理特征的侵袭性B细胞淋巴瘤。然而，在新的肿瘤分类模式下，R-CHOP是否能继续作为PMBCL的标准一线免疫化疗方案仍存在争议。DA-EPOCH-R与R-CHOP方案的疗效相当，但需注意药物的毒性反应。虽然PMBCL是一种放射敏感性的恶性肿瘤，但放疗并不作为PMBCL的常规治疗选择，免疫化疗后PET/CT仍阳性的患者需要活检证实以制定进一步治疗方案。复发/难治性PMBCL预后差，常采用挽救性免疫化疗，随后进行大剂量化疗和自体干细胞移植。复发/难治性PMBCL通常存在PD-1过表达，免疫检查点抑制剂潜在成为其重要的治疗方式。近年来，分子医学的发展为PMBCL靶点选择提供了新的依据，但有待进一步的临床试验证实。

关键词: 淋巴瘤, B细胞, 放射疗法, 利妥昔单抗, 化学疗法

Abstract: Primary mediastinal B-cell lymphoma (PMBCL) is aggressive Bcell lymphoma with unique clinicopathologic characteristics. However, under the new classification of PMBCL, whether R-CHOP was the standard first-line immunotherapy regimen remains a controversy. The DA-EPOCH-R is not inferior to R-CHOP, but attention should be paid to the toxic effects. PMBCL is a radiosensitive disease, but radiotherapy did not as the front-line therapy for PMBCL. A biopsy is required for positive PET/CT after immunotherapy-chemotherapy to determine the further treatment of PMBCL. Recurrent/refractory PMBCL, with poor prognosis, salvage immunochemotherapy is often used followed by high-dose chemotherapy and autologous stem cell transplant. PD-1 overexpression is common in recurrent/refractory PMBCL, and immune checkpoint inhibitors are potential to be an important treatment option. Recently, the development of molecular medicine has provided a new basis for the selection of targets in PMBCL, however, it needs to be further confirmed by clinical trials.

Key words: Lymphoma, B-cell, Radiotherapy, Rituximab, Chemotherapy

相明月, 王丽丽, 韩大力. 原发性纵隔B细胞淋巴瘤治疗的研究进展[J]. 国际肿瘤学杂志, 2019, 46(8): 505-508.

Xiang Mingyue, Wang Lili, Han Dali. Progress of treatment for primary mediastinal B-cell lymphoma[J]. Journal of International Oncology, 2019, 46(8): 505-508.

参考文献

［1］ Ceriani L, Milan L, Johnson PWM, et al. Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume［J］. Eur J Nucl Med Mol Imaging, 2019, 46(6): 1334-1344. DOI: 10.1007/s00259-019-04286-8. ［2］ Lees C, Keane C, Gandhi MK, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions［J］. Br J Haematol, 2019, 185(1): 25-41. DOI: 10.1111/bjh.15778. ［3］ Shah NN, Szabo A, Huntington SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis［J］. Br J Haematol, 2018, 180(4): 534-544. DOI: 10.1111/bjh.15051. ［4］ Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal large B-cell lymphoma［J］. Criti Rev Oncol Hematol, 2017, 113: 318-327. DOI: 10.1016/j.critrevonc.2017.01.009. ［5］ Lisenko K, Dingeldein G, Cremer M, et al. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma［J］. BMC Cancer, 2017, 17(1): 359. DOI: 10.1186/s12885-017-3332-3. ［6］ Gleeson M, Hawkes EA, Cunningham D, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial［J］. Br J Haematol, 2016, 175(4): 668-672. DOI: 10.1111/bjh.14287. ［7］ Shah NN, Fenske TS, Hamadani M, et al. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al［J］. Br J Haematol, 2019, 184(5): 838-840. DOI: 10.1111/bjh.15183. ［8］ GiulinoRoth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R［J］. Br J Haematol, 2017, 179(5): 739-747. DOI: 10.1111/bjh.14951. ［9］ Wilson WH, sinHo J, Pitcher BN, et al. Phase Ⅲ randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303［J］. Blood, 2016, 128(22): 469. ［10］ GiulinoRoth L. How I treat primary mediastinal B-cell lymphoma［J］. Blood, 2018, 132(8): 782-790. DOI: 10.1182/blood-2018-04-791566. ［11］ Jackson MW, Rusthoven CG, Jones BL, et al. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma［J］. Am J Hematol, 2016, 91(5): 476-480. DOI: 10.1002/ajh.24325. ［12］ Melani C, Advani R, Roschewski M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making［J］. Haematologica, 2018, 103(8): 1337-1344. DOI: 10.3324/haematol.2018.192492. ［13］ Messmer M, Tsai HL, Varadhan R, et al. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma［J］. Leuk Lymphoma, 2019, 60(5): 1261-1265. DOI: 10.1080/10428194.2018.1519812. ［14］ Giri S, Bhatt VR, Pathak R, et al. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis［J］. Am J Hematol, 2015, 90(11): 1052-1054. DOI: 10.1002/ajh.24172. ［15］ De Sanctis V, Alfò M, Di Rocco A, et al. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: results from a monoinstitutional cohort analysis of long-term survivors［J］. Hematol Oncol, 2017, 35(4): 554-560. DOI: 10.1002/hon.2377. ［16］ Bhatt VR, Mourya R, Shrestha R, et al. Primary mediastinal large B-cell lymphoma［J］. Cancer Treat Rev, 2015, 41(6): 476-485. DOI: 10.1016/j.ctrv.2015.04.006. ［17］ Ceriani L, Barrington S, Biggi A, et al. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study［J］. Hematol Oncol, 2017, 35(4): 548-553. DOI: 10.1002/hon.2339. ［18］ Aoki T, Shimada K, Suzuki R, et al. Highdose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma［J］. Blood Cancer J, 2015, 5: e372. DOI: 10.1038/bcj.2015.101. ［19］ Avivi I, Boumendil A, Finel H, et al. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation［J］. Bone Marrow Transplant, 2018, 53(8): 1001-1009. DOI: 10.1038/s41409-017-0063-7. ［20］ Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12［J］. J Clin Oncol, 2014, 32(31): 3490-3496. DOI: 10.1200/jco.2013.53.9593. ［21］ Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma［J］. Leuk Lymphoma, 2008, 49(7): 1329-1336. DOI: 10.1080/10428190802108870. ［22］ Mottok A, Wright G, Rosenwald A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens［J］. Blood, 2018, 132(22): 2401-2405. DOI: 10.1182/blood-2018-05-851154. ［23］ Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma［J］. Blood, 2017, 130(3): 267-270. DOI: 10.1182/blood-2016-12-758383. ［24］ Zinzani PL, Thieblemont C, Melnichenko V, et al. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial［J］. Hematol Oncol, 2017, 35(S2): 62-63. DOI: 10.1002/hon.2437_49. ［25］ Yassin R, Hajeer A, Alshieban S, et al. HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma［J］. Curr Res Transl Med, 2019, 67(1): 31-33. DOI: 10.1016/j.retram.2018.11.001. ［26］ Sauter CS, Matasar MJ, Schoder H, et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL［J］. Blood, 2018, 131(16): 1805-1808. DOI: 10.1182/blood-2017-08-802561. ［27］ Svoboda J, Landsburg DJ, Dwivedy Nasta S, et al. Brentuximab vedotin with R-CHP chemotherapy as frontline treatment for patients with CD30 positive primary mediastinal large B-cell, diffuse large B-cell, and grey zone lymphomas: results of a phase Ⅰ/Ⅱ multisite trial［J］. 2017, 130(Suppl 1): 191. ［28］ Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma［J］. N Engl J Med, 2017, 377(26): 2531-2544. DOI: 10.1056/NEJMoa1707447.

[1]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[6]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[7]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[8]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[9]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[10]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[11]	李进芝, 赵彪, 文晓博, 张明, 袁美芳, 孙梦真, 蒲琴, 杨毅. Monaco系统计算网格尺寸对T₄期鼻咽癌的剂量学影响[J]. 国际肿瘤学杂志, 2023, 50(11): 641-649.
[12]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[13]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇. 重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.
[14]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 新型冠状病毒感染疫情背景下肿瘤患者放射治疗管理相关问题中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(10): 577-584.
[15]	王瑾, 李若阳, 赵雪巍, 李辉, 周志国, 赵静霞. 盐酸美金刚治疗放射性认知功能障碍及其与维生素联合应用的研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 622-626.

原发性纵隔B细胞淋巴瘤治疗的研究进展

Progress of treatment for primary mediastinal B-cell lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价